Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated ...

and the inhibition of this pathway by a FGFR1 inhibitor reversed KLX's effects. These findings highlight the role of KLX in modulating key signaling pathways involved in EndMT and atherosclerosis ...

and the inhibition of this pathway by a FGFR1 inhibitor reversed KLX's effects. These findings highlight the role of KLX in modulating key signaling pathways involved in EndMT and atherosclerosis ...

Researchers have identified in a new study that oral infigratinib, an FGFR1-3 selective tyrosine kinase inhibitor, improves ...

LUAD is frequently associated with mutations in EGFR, KRAS, ALK, and BRAF, while LUSC is more commonly linked to alterations in PIK3CA, FGFR1 ... EGFR tyrosine kinase inhibitors (TKIs) have ...